TNXP
Tonix Pharmaceuticals Holding Corp.
Key Financials
Operating Income
$-125703000
↑ 8.0%
Revenue
$13.1M
↑ 29.8%
Net Income
$-124021000
↑ 4.6%
Total Assets
$277.2M
↑ 70.2%
EPS (Diluted)
$-14.57
↑ 91.7%
Total Liabilities
$32.0M
↑ 37.2%
Cash & Equivalents
$207.6M
↑ 110.2%
Shareholders' Equity
$245.2M
↑ 75.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/13/2026 | View on SEC |
| 10-Q | 8/10/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
| 8-K | 7/21/2026 | View on SEC |
| 8-K | 7/13/2026 | View on SEC |
| 4 | 7/9/2026 | View on SEC |
| S-8 | 7/1/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TNXP |
| Company Name | Tonix Pharmaceuticals Holding Corp. |
| CIK | 1430306 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 212-980-9155 |